Friday, 16 October 2026European Markets

CHAUSSERIA Stock Is 33% Up In The Last 21 Sessions

Loading stream...

chausseria's, a renowned firm listed in the cac 40 index, has recently seen a significant increase in its share price. the shares have shown a rise of 33% over 21 sessions, soaring from the value of eur5 to eur6.65. this increase comes after an unfortunate spell of five consecutive sessions of losses for the company's shareholders.

chausseria's stock rise amidst cac 40's decline

interestingly, chausseria's rise in stock value is observed at a time when the cac 40 index, france's benchmark stock market index, is facing a downslide. the index has dropped 1.35% following three consecutive sessions of losses, closing at eur7,315.07. even with recent gains, it still falls short by 16.888% from its 52-week high of eur8.00.

about chausseria's operation and earnings

chausseria, celebrated for designing, manufacturing, and marketing women's footwear under its chausseria and janie philip brands, disclosed an earnings per share (eps) of eur0.47 during its last twelve-month fiscal period. in the current scenario, the firm's eps equates to a trailing twelve-month price-to-earnings (p/e) ratio of 14.15. this suggests that for every euro of annual earnings generated by this business, investors are currently spending eur14.15.

chausseria's profitability metrics

exploring the profitability metrics of the company reveals a promising picture. the company's return on equity (a crucial metric measuring profitability relative to shareholder equity) for the past year was recorded at 4.29%

exceeding moving average and trading volume

chausseria's present equity value surpasses both its 50-day moving average of eur5.16 and 200-day moving average of eur5.20 significantly. also, worth noting is the recent surge in its trading, with the volume increasing by an impressive 419.23% above its usual volume of 26. this increase might be indicative of amplified investor enthusiasm, which together with robust performance metrics and sustained business operations, could positively boost chausseria stock value in the future.

more news about chausseria (chsr.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com